Propofol
| Evidence Level: L2 | Predicted Indications: 5 |
Table of Contents
Propofol: From General Anesthesia to Migraine Disorder
One-Sentence Summary
Propofol is an intravenous anesthetic and sedative-hypnotic. The data compiled for this report do not include a US-approved indication text for it. The TxGNN model predicts it may be effective for migraine disorder, with 3 clinical trials and 20 publications currently supporting this direction, including several randomized controlled trials in the emergency department.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the available license records (propofol is generally known as an intravenous anesthetic/sedative) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L2 |
| US Market Status | Cancelled only (all 9 licenses listed as cancelled) |
| Number of NDAs | 9 licenses (1 NDA and 8 ANDAs) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the compiled data. Based on the mechanistic rationale in the data, propofol is a GABA-A positive allosteric modulator. Enhanced GABAergic inhibition may dampen trigeminovascular pain signaling and cortical hyperexcitability.
In preclinical work, propofol hemisuccinate suppressed cortical spreading depression (PMID 22390898). This phenomenon is believed to underlie migraine aura and may also trigger migraine pain. This offers a plausible biological link between a sedative-hypnotic and migraine.
In practice, low (sub-anesthetic) doses have been used for refractory migraine in the emergency department. Because of the risks of sedation and respiratory depression, use is limited to monitored settings.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01604785 | Phase 2/3 | Completed | 74 | Low-dose propofol as abortive therapy for pediatric migraine in the emergency department; the registry record does not show results |
| NCT02485418 | N/A | Completed | 40 | Low-dose propofol infusion for pediatric migraine; evaluates efficacy, safe dosing limits and duration of effect |
| NCT02492295 | N/A | Terminated | 12 | Low-dose propofol for severe refractory migraine in the emergency department; terminated early and underpowered |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29456086 | 2018 | RCT | J Emerg Med | Prospective randomized trial of low-dose propofol for pediatric migraine in the emergency department |
| 32705801 | 2020 | Pilot RCT | Emerg Med Australas | Procedural-sedation-dose propofol compared with standard therapy for initial migraine management in the emergency department |
| 35573713 | 2022 | RCT | Arch Acad Emerg Med | Sumatriptan plus propofol compared with sumatriptan alone in acute migraine |
| 35402989 | 2022 | RCT | Arch Acad Emerg Med | Propofol plus granisetron compared with propofol plus metoclopramide for acute migraine symptoms |
| 31621134 | 2020 | Systematic Review | Acad Emerg Med | Reviews safety and efficacy of propofol for acute migraine in the emergency department; existing evidence is limited |
| 26790849 | 2016 | Systematic Review | Headache | Qualitative review of acute treatments for pediatric migraine in the emergency department |
| 39364614 | 2024 | Systematic Review / Network Analysis | Headache | Compares parenteral agents for reducing relapse after severe acute migraine |
| 41321235 | 2026 | Guideline | Headache | Updated American Headache Society guideline on parenteral drugs for acute migraine in the emergency department |
| 27454834 | 2016 | Review | Expert Rev Neurother | Drug profile of sub-anesthetic propofol in super-refractory migraine |
| 10759925 | 2000 | Clinical report | Headache | Reports unique effectiveness of intravenous propofol in intractable migraine in an outpatient headache center |
Another trial, a double-blind randomized trial of propofol versus placebo in adult emergency department patients (PMID 33070469), was identified under the related subtype migraine with brainstem aura.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA019627 | Diprivan (Fresenius Kabi) | Injectable emulsion | Not stated; license cancelled |
| ANDA075102 | Propofol (Sagent) | Injectable emulsion | Not stated; license cancelled |
| ANDA074848 | Propofol (Hikma) | Injectable emulsion | Not stated; license cancelled |
| ANDA205067 | Propofol Injectable Emulsion (Dr. Reddy’s) | Injectable emulsion | Not stated; license cancelled |
| ANDA205576 | Propofol (Pfizer) | Injectable emulsion | Not stated; license cancelled |
There are 9 licenses in total, all listed as cancelled; the table shows the 5 main ones.
Safety Considerations
- Disease-level contraindication signals (knowledge graph, not label text): epilepsy, hypotensive disorder, respiratory failure, intracranial arteriosclerosis, inherited lipid metabolism disorder and familial hyperlipidemia.
- Clinical setting: sedation and respiratory depression risk limit use to monitored settings such as the emergency department.
- Drug Interactions: 100 interactions were identified. Most listed are moderate, such as famotidine, clarithromycin, levofloxacin, ondansetron, granisetron, dolasetron, cisapride, morphine and opium, as well as several laxatives (bisacodyl, lactulose, magnesium citrate). Metronidazole is minor.
Please refer to the package insert for the full warnings and contraindications, which were not available in the compiled data.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several randomized trials and systematic reviews support low-dose propofol for acute migraine in the emergency department, including pediatric populations. However, the trials are small, one was terminated early, and the evidence is mostly limited to monitored settings. All US licenses are currently cancelled, and label safety data are missing.
To proceed, the following is needed:
- Obtain and review the FDA package insert warnings and contraindications (currently a blocking gap)
- Confirm the mechanism of action from DrugBank
- Appraise the RCT results (efficacy, relapse and adverse events) in a formal evidence synthesis
- Define a monitored-use protocol (dosing, respiratory and hemodynamic monitoring, exclusion of patients with respiratory failure, hypotension or epilepsy)
- Clarify the regulatory and supply status given the cancelled US licenses
Other Predicted Indications (for reference)
| Predicted Indication | TxGNN Score | Evidence Level | Decision | Comment | |——|——|——|——|——| | Migraine with brainstem aura | 99.58% | L3 | Research Question | Plausible mechanism through cortical spreading depression, but no subtype-specific evidence; sedation and respiratory depression are more consequential in brainstem dysfunction | | Prinzmetal angina | 99.23% | L4 | Hold | Case reports describe coronary spasm triggered during anesthesia, which is a safety signal rather than a benefit | | Nephrogenic syndrome of inappropriate antidiuresis | 99.20% | L5 | Hold | No mechanistic link or evidence | | Tourette syndrome | 99.03% | L4 | Hold | Evidence concerns propofol as sedation during deep brain stimulation surgery, not as a treatment for tics |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.